Diabetic foot treatment is focus of Dec. 8-10 conference

December 2, 2016

Attention, health care providers with interest in surgical management of the diabetic foot: The UT Health Science Center at San Antonio announces the 11th Annual International External Fixation Symposium, set for Dec. 8-10 at the La Cantera Hill Country Resort. Registration is still open for this multidisciplinary continuing education conference, which will feature state-of-the-art lectures […]

diabetes in men

AJMC.com: As Metformin Combinations Proliferate, Questions Arise About Value

September 10, 2016

Earlier this year, when the FDA granted initial approval to Jentadueto XR and a first-line indication to Invokamet, it gave fresh momentum to an entire category of medications: single pills that combine metformin with some other treatment for type 2 diabetes (T2D).  – See more at: http://www.ajmc.com/journals/evidence-based-diabetes-management/2016/september-2016/as-metformin-combinations-proliferate-questions-arise-about-value#sthash.jAAOQ94L.dpuf Read the full story at AJMC.com

Research shows Hispanics living with HIV at high risk of developing diabetes and obesity

September 6, 2016

Patients receiving life-saving, anti-retroviral treatment for HIV are living longer and healthier lives. But there is a downside: As they age, individuals living with HIV are at greater risk of developing heart disease and other chronic health conditions due to HIV-associated inflammation as well as the medications that control the virus. This can pose special problems for patients who live in lower- and middle-income Latin American countries, such as Mexico and the Dominican Republic, where resources for primary care are limited, according to a new study in the August edition of the journal PLOS ONE.



MedPage Today: Triple Combo Tx Durable for T2D

September 1, 2016

Starting newly-diagnosed diabetes patients on the triple combination of metformin/pioglitazone/exenatide upfront provided better glucose control with less hypoglycemia than a standard sequential regimen, 3-year follow-up from the EDICT trial showed. Read the full story at MedPage Today